GlassScriptPhysician profile
Avery S Kuflik
NPI 1952415705
$9,393.96
in general payments reported to CMS, 2019-2025
24 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2021: $93.19 · 2022: $458 · 2023: $4,723 · 2024: $1,707 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,200 · Food and Beverage: $3,773 · Education: $420 · Travel and Lodging: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,200.00 |
| Food and Beverage | $3,773.45 |
| Education | $420.25 |
| Travel and Lodging | $275.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,209.19 | 2021-2025 | Ilumya, Winlevi |
| Botanix Sb INC | $1,476.85 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $660.74 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $501.69 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $398.88 | 2022-2024 | Tremfya |
| Incyte Corporation | $297.51 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $220.24 | 2025 | Nemluvio, Aklief |
| Amgen INC. | $218.58 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $210.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $152.58 | 2024-2025 | Dupixent, Libtayo |
| Almirall LLC | $149.51 | 2019 | |
| Leo Pharma INC. | $139.94 | 2022-2024 | Adbry |
| Journey Medical Corporation | $133.37 | 2022 | |
| Abbvie INC. | $126.69 | 2023-2025 | |
| Biofrontera INC. | $111.18 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $103.80 | 2024 | Tolak |
| Ucb, INC. | $60.00 | 2021-2024 | Bimzelx |
| Paratek Pharmaceuticals, INC. | $54.07 | 2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $48.56 | 2019-2025 | |
| Organogenesis INC. | $35.46 | 2024-2025 | Cygnus Dual |
| Pfizer INC. | $34.40 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.76 | 2023-2025 | Cabtreo, Arazlo |
| Lilly USA, LLC | $18.96 | 2023 | Olumiant, Taltz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,401.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Kuflik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.